SEC Form 4 · accession 0001684531-26-000002
CG Oncology, Inc. · CGON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Mulay
Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 16, 2026 · 5:07 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001991792
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2026 | M | 654 | $3.72 | A | 654 | D | |
| Common Stock | Jun 15, 2026 | S | 654 | $60.12 | D | 0 | D | |
| Common Stock | Jun 15, 2026 | M | 1,310 | $12.59 | A | 1,310 | D | |
| Common Stock | Jun 15, 2026 | S | 1,310 | $60.12 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F2 | $3.72 | Jun 15, 2026 | M | 654 | D | — | Jun 13, 2033 | Common Stock | 654 | 0 | D |
| Director Stock Option (right to buy)F3 | $12.59 | Jun 15, 2026 | M | 1,310 | D | — | Dec 12, 2033 | Common Stock | 1,310 | 2,620 | D |
Explanation of responses
- F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.
- F2The stock option vested in 36 substantially equal monthly installments beginning on July 14, 2023.
- F3The stock option vests in 36 substantially equal monthly installments beginning on January 13, 2024.